U.S. Antibiotics Market

U.S. Antibiotics Market Size (2024 to 2029)

The size of the antibiotics market in the United States is estimated to be growing at a CAGR of 6.04% during the forecast period.

The rising prevalence of chronic diseases and infections in the U.S. majorly drives the growth of the U.S. antibiotics market growth. The population suffering from chronic diseases such as cancer, cardiovascular diseases, diabetes, and arthritis is on the rise in the U.S. and growing rapidly, which is further resulting in increasing healthcare expenditure. In cases of infectious diseases, antibiotics are commonly prescribed to kill bacteria or prevent their spread throughout the body. Such diseases include cellulitis, urinary tract infection, genital herpes, and rheumatic fever. Healthcare providers typically recommend the use of antibiotic tablets to hasten recovery and reduce the severity of such illnesses.

The growing investments and increased focus on research and development by the pharmaceutical companies to develop improved and effective antibiotics further contribute to the U.S. antibiotics market growth. The notable pharmaceutical companies in the U.S. have been investing significant resources to manufacture antibiotics with varying dosages for all age groups to address the growing demand for antibiotics due to the increasing patient population suffering from chronic and infectious diseases. The increasing mortality rates due to new infections among the population have further spurred researchers to develop drug combinations that can effectively combat infections and prevent critical situations in patients' lifetimes. Moreover, increasing support from the U.S. government and an increasing number of drug approvals support the growth of the U.S. antibiotics market.

The rising awareness among the U.S. population regarding the availability of various antibiotics boosts the growth rate of the U.S. antibiotics market. In addition, the rising antibiotic resistance and need for new treatments, growing healthcare expenditure, increasing demand for effective treatments, rapid adoption of technological advancements in the manufacturing of antibiotics, raising awareness about the need for limited antibiotic use and favorable government initiatives and policies to support antibiotic development and usage boost the growth rate of the U.S. antibiotics market.

Furthermore, the growing adoption of antibiotics by the population for self-treatment, increasing literacy rates among the population, leading to increased awareness about the availability and benefits of antibiotics and the growing number of partnerships and collaborations between pharmaceutical companies and research institutions for the development of antibiotics favor the growth rate of the U.S. antibiotics market.

On the other hand, the potential side effects such as itchy skin, coughing and breathing difficulties of antibiotics that can impact patient health hamper the growth of the U.S. antibiotics market. In addition, the increasing prevalence of self-medication practices and associated side effects, the high cost of developing novel antibiotics and the lengthy approval process for new drugs impede the U.S. antibiotics market growth. Furthermore, the lack of availability of advanced drugs in pharmacy stores is another significant roadblock to the growth of the U.S. antibiotics market.

This research report on the U.S. antibiotics market has been segmented and sub-segmented based on the following categories.

By Action Mechanism:

• Cell Wall Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Rna Synthesis Inhibitors
• Mycolic Acid Synthesis Inhibitors
• Folic Acid Synthesis Inhibitors

By Drug Class:

• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Aminoglycosides
• Sulfonamides
• Others

By Country:

• The United States

Among all the countries, the U.S. antibiotics market held the leading share in the worldwide market in 2023 and is anticipated to grow at a promising CAGR during the forecast period. Owing to the availability of a wide range of antibiotic drugs and the increasing healthcare expenditure by the U.S. population, the U.S. antibiotics market is anticipated to grow notably during the forecast period. The US FDA approved several novel antibiotic drugs after conducting numerous clinical trials to mitigate the potential side effects for users. Furthermore, the rising number of clinical trial centers and new variants of the coronavirus also contribute to the market's demand. Among the states in the US, California and Washington, DC, have emerged as key contributors to the market's growth. In California, antibiotics are also used to prevent and control infections among animals and livestock, thereby reducing the risk of spreading the infection to humans. Additionally, the government has undertaken several surveys to monitor the usage of antibiotic drugs among animals for better prevention of infections. In Washington DC, antibiotics are used as per doctor's prescriptions to minimize the potential side effects among the population. Many hospitals and clinics in this state have adopted oral, tonic, and injection-based antibiotic drugs to provide effective treatment to patients.

KEY MARKET PLAYERS:

Johnson and Johnson, GlaxoSmithKline, Pfizer PLC, Bayer AG, Novartis AG, Abbott Inc., Merck & Co. Inc., Sanofi SA, and F. Hoffmann-La Roche AG are some of the notable companies in the U.S. antibiotics market.